Search tips
Search criteria 


Logo of agpsychBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleAnnals of General Psychiatry
Ann Gen Psychiatry. 2010; 9(Suppl 1): S169.
Published online 2010 April 22. doi:  10.1186/1744-859X-9-S1-S169
PMCID: PMC2991857

Use of antipsychotics in the treatment of major depressive disorder in an outpatient mental health center


Antidepressants are currently the mainstay of treatment for depression; however, almost two thirds of patients will fail to achieve remission with initial treatment. Evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms [1].

Materials and methods

Using a sample of 100 patients with MDD who have been visited in Barcelona's Sant Martí Sud outpatient mental health center during the year 2008, sociodemographical (gender, age) and clinical data (toxic consume, psychiatric background, use of antipsychotics) are analysed with SPSS 15.0 statistical package


Antipsychotics are used in 27% of the patients, with a predominancy in the female gender (77.8%), a global average age of 57.9 ± 12.6 years. There is a predominancy of absence of psychiatric background (55.6%) and the absence of previous hospitalisations (66.7%). In 96.3% of the sample there was no toxic abuse.

It is observed the following distribution in the use of antipsychotics: quetiapine and olanzapine (29.6% each one), risperidone (26%), paliperidone (3%). Average dose was 5.7 mg/d for olanzapine, 2.3 mg/d for risperidone, 84.5 mg/d for quetiapine and 6 mg/d for paliperidone.


It is observed an important frequency in the use of antipsychotic treatment for MDD, in relation with the fact that there is growing evidence for the efficacy of atypical antipsychotics for adjunctive treatment of depressive symptoms of MDD. There is scientific evidence that supports the use of the two antipsychotics predominantly used in our sample (olanzapine and quetiapine) [2], but more studies are needed to establish its place in management.


  • Craig Nelson J, Pikalov A, Berman R. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937–948. [PMC free article] [PubMed]
  • Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–4. doi: 10.1176/appi.ajp.158.1.131. [PubMed] [Cross Ref]

Articles from Annals of General Psychiatry are provided here courtesy of BioMed Central